{"nctId":"NCT02509481","briefTitle":"Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study","startDateStruct":{"date":"2015-06"},"conditions":["Malaria","Lymphatic Filariasis"],"count":2712,"armGroups":[{"label":"Single MDA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ivermectin","Drug: Albendazole"]},{"label":"Repeated MDA","type":"EXPERIMENTAL","interventionNames":["Drug: Ivermectin","Drug: Albendazole"]}],"interventions":[{"name":"Ivermectin","otherNames":["Mectizan"]},{"name":"Albendazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Residence in the study site\n* Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is \\< 18 years)\n\nExclusion Criteria:\n\n* Residence outside of in the study site\n* Height ≤ 90 cm\n* Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension\n* Pregnancy\n* Breast feeding if infant is within 1 week of birth\n* Known allergy to the study drugs","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Clinical Malaria Episodes","description":"Cumulative incidence of malaria episodes in a cohort of village children ≤ 5 years of age (as assessed by active case surveillance in study villages - malaria episode defined as ≥38.0°C fever or history of fever in the last 24 hours + positive rapid diagnostic test for Plasmodium falciparum). Incidence is reported as malaria episodes per child over the course of the trial, a higher incidence is a worse outcome.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"The number of adverse events. Adverse events data were collected via passive case detection from total population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Entomological Indicator of Parasite Transmission","description":"Change in human IgG reactivity (optical density; ∆OD) to an Anopheles salivary gland antigen (peptide gSG6-P1) over the trial period. A score of 0 indicates no change in seroreactivity from from immediately before to immediately after the trial, suggesting consistent mosquito biting throughout the trial. A positive score indicates increasing seroreactivity and thus increasing mosquito biting on participants from immediately before to immediately after the trial. A negative score indicates decreasing seroreactivity and thus decreasing mosquito biting on participants from immediately before to immediately after the trial.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.057","spread":null},{"groupId":"OG001","value":"-0.124","spread":null}]}]}]},{"type":"SECONDARY","title":"Molecular Force of P. Falciparum Infection","description":"Examination of new P. falciparum clones acquired from the beginning to the end of the intervention (molecular force of infection; mFOI) per child. Molecular genotyping used capillary blood taken at the time of diagnosis of each positive malaria episode and consisted of nPCR of the msp2 gene. We calculated the multiplicity of infection (MOI) per malaria episode, and then calculated the molecular force of infection (mFOI) associated with malaria episodes per child (over course of the trial)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH)","description":"Prevalence of soil transmitted helminth infections in children between 6-10 years old from the beginning to the end of the intervention","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Entomological Inoculation Rate","description":"The entomological inoculation rate (EIR per week per person) is the measure of the human biting rate per person per week, multiplied by the sporozoite rate (in biting mosquitoes) per week, an estimated from sampling mosquitoes from 8 households located in the center of each study village. The EIR was calculated for each of the 6 sampling weeks of the treatment phase.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2069","spread":"0.2376"},{"groupId":"OG001","value":"0.1972","spread":"0.2084"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":1265},"commonTop":["acute malnutrition","malaria","pruritis","vomiting","fever"]}}}